Pre-Open Movers 12/11: (PTI) (OLLI) (PLAB) Higher (ITRM) (GME) (PLCE) Lower (more...)
Today's Pre-Open Movers
Iterum Therapeutics plc (Nasdaq: ITRM) 46.2% LOWER; announced topline results from its Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial in complicated intra-abdominal infections (cIAI). The primary U.S. Food and Drug Administration (FDA) endpoint was clinical response on Day 28 in the micro-MITT population. In this population, the difference in outcomes was 4.7% with a 95% confidence interval on that difference of -10.3% to 1.0%. Non-inferiority required that the lower limit of the difference in the outcome rates be >-10% for FDA.
GameStop (NYSE: GME) 18.9% LOWER; reported Q3 EPS of ($0.49), $0.60 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.62 billion. GameStop sees FY2019 EPS of $0.10-$0.20, versus the consensus of $1.21.
Children's Place (NASDAQ: PLCE) 15.7% LOWER; reported Q3 EPS of $3.03, $0.01 better than the analyst estimate of $3.02. Revenue for the quarter came in at $524.8 million versus the consensus estimate of $534.09 million. Children's Place sees FY2019 EPS of $5.00-$5.20, versus the consensus of $5.62. Children's Place sees FY2019 revenue of $1.862-1.867 billion, versus the consensus of $1.92 billion. A comparable retail sales decrease of approximately 3%. Children's Place sees Q4 2019 EPS of $1.48-$1.68, versus the consensus of $2.06. Children's Place sees Q4 2019 revenue of $504-509 million, versus the consensus of $555.13 million.
Aquestive Therapeutics, Inc. (Nasdaq: AQST) 15.2% LOWER; announced that it intends to offer and sell $35 million of shares of its common stock in an underwritten public offering.
Proteostasis Therapeutics, Inc. (NASDAQ: PTI) 11.8% HIGHER; announced positive, initial ex-vivo results of PTI's proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators, PTI-801, PTI-808, and PTI-428, in individuals with CF who are ineligible for the current standard of care CFTR modulator therapies due to their genotype. The data are part of a pan-European strategic initiative, known as HIT-CF (Human Individualized Therapy of CF), which seeks to accelerate the development of, and access to, personalized therapies for CF patients, beginning with those for whom no currently approved CFTR modulator therapy is indicated.
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) 10.7% HIGHER; announced positive topline results from the in-clinic stage of a Phase 2 study of its developmental ready-to-use (RTU) glucagon in patients who experience postprandial hypoglycemic episodes following bariatric surgery.
Ollie's Bargain Outlet (NASDAQ: OLLI) 10.6% HIGHER; reported Q3 EPS of $0.41, $0.03 better than the analyst estimate of $0.38. Revenue for the quarter came in at $327 million versus the consensus estimate of $322.53 million. Reaffirms. Names John Swygert President and Chief Executive Officer and member of its board of directors, effective immediately.
United Natural Foods (NASDAQ: UNFI) 9.3% LOWER; reported Q1 EPS of $0.12, $0.16 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $6 billion versus the consensus estimate of $5.8 billion. United Natural Foods sees FY2020 EPS of $1.22-$1.76, versus the consensus of $1.38. United Natural Foods sees FY2020 revenue of $23.5-24.3 billion, versus the consensus of $23.84 billion.
Photronics, Inc. (NASDAQ: PLAB) 8.2% HIGHER; reported Q4 EPS of $0.15, in-line with the analyst estimate of $0.15. Revenue for the quarter came in at $156.3 million versus the consensus estimate of $147.37 million.
American Eagle Outfitters (NYSE: AEO) 8% LOWER; reported Q3 EPS of $0.48, in-line with the analyst estimate of $0.48. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.06 billion. Comparable Sales Rose 5%, Marking 19 Consecutive Quarters of Growth. American Eagle Outfitters sees Q4 2019 EPS of $0.34-$0.36, versus the consensus of $0.46.
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) 7.8% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Global Medical REIT Inc. (NYSE: GMRE) 7.4% LOWER; commenced an underwritten public offering of 4,750,000 shares of its common stock, par value $0.001 per share, subject to market and other conditions.
Choice Hotels International Inc. (NYSE: CHH) 5.9% HIGHER; will replace Plantronics Inc. (NYSE: PLT) in the S&P MidCap 400
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) 5.7% LOWER; announces that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock.
Vera Bradley (NASDAQ: VRA) 5.6% HIGHER; reported Q3 EPS of $0.20, $0.02 better than the analyst estimate of $0.18. Revenue for the quarter came in at $127.5 million versus the consensus estimate of $124.47 million. Vera Bradley sees Q4 EPS of $0.49-$0.53, versus the consensus of $0.52. Vera Bradley sees Q4 Revenues of $155-$162 million, versus the consensus of $162.52 million. Vera Bradley sees FY2020 EPS of $0.90-$0.94, versus the consensus of $0.90. Vera Bradley sees FY2020 Revenues of $492-$500 million, versus the consensus of $497.4 million.
Impinj, Inc. (Nasdaq: PI) 4% LOWER; announced its intention to offer, subject to market conditions and other factors, $75 million aggregate principal amount of Convertible Senior Notes due 2026 (the notes) in a private offering.
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) 3.4% LOWER; Announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common stock.
Dave & Buster's Entertainment (NASDAQ: PLAY) 3% HIGHER; reported Q3 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $299.4 million versus the consensus estimate of $296.36 million. Dave & Buster's Entertainment sees FY2019 revenue of $1.347-1.354 billion, versus the consensus of $1.35 billion.
The RealReal Inc. (NASDAQ: REAL) 1.7% HIGHER; DA Davidson initiates coverage with a Buy rating, price target $22..